RESEARCH CONTEXT / DOSE · ROUTE · PK
TB-500 dosage in the research literature, and why the fragment has no validated human half-life
The doses studies actually administered, to which species, by which route — and the plain fact that the heptapeptide has no validated human pharmacokinetic profile of its own.
TB-500 dosage in the research literature
TB-500 dosage in the research literature is described as study parameters, not as a human protocol, and the figures span a wide range because the models do. Animal studies dose full-length thymosin beta-4 broadly: roughly 6–12 mg/kg in some cardiac and neuro rodent models; 2, 12, and 18 mg/kg intraperitoneally in the embolic-stroke dose-response study, with a modeled optimal near 3.75 mg/kg [4]; and 150 µg twice weekly intraperitoneally for 6 months in the mdx muscular-dystrophy study [5]. Picogram-to-nanogram amounts are bioactive in vitro — about 10 pg was active in keratinocyte migration assays [3].
Human dosing exists only for the parent protein. The Phase 1 study dosed synthetic Tβ4 intravenously at 42, 140, 420, and 1260 mg — a single dose, then daily for 14 days — and reported tolerability across all four cohorts [6]. The predominant route in rodent efficacy work is intraperitoneal; intravenous, topical, and ophthalmic routes appear in the cardiac and corneal/dermal literature [5]. None of these figures is a recommendation, and none is a validated protocol for the TB-500 heptapeptide in humans.
A recurring and important point: non-clinical "loading then maintenance" protocols circulated in athletic and peptide-research communities are not derived from controlled human trials and have no published clinical validation [5]. The non-monotonic stroke dose-response — where 18 mg/kg gave no benefit while 2 and 12 mg/kg did — directly undercuts the assumption that more is better that those loading schemes rest on [4].
Routes, handling, and why the numbers don't transfer cleanly
The route a study used is as load-bearing as the dose, and they vary by purpose. Intraperitoneal injection predominates in rodent efficacy work — it is how the wound, stroke, and dystrophy studies delivered Tβ4 [3][4][5]. Intravenous delivery appears in the human Phase 1 and in some cardiac models [6][5]. Topical and ophthalmic routes carry the corneal and dermal wound work, including the clinical-grade topical Tβ4 formulation studied in dry-eye trials [5]. Subcutaneous and intramuscular routes circulate in community research-use, but those are not the routes of the controlled efficacy studies [5]. A milligram-per-kilogram figure from an intraperitoneal rat study is not interchangeable with a human intravenous dose, and neither was generated for the isolated heptapeptide.
There is also a potency span worth keeping in view. The same literature that reports milligram-per-kilogram systemic doses also reports picogram-level in-vitro activity — roughly 10 pg stimulated keratinocyte migration 2–3-fold [3], and nanomolar Tβ4 stimulates hair-follicle stem cells [5]. The amount that moves a cell in a dish and the amount given to a whole animal are orders of magnitude apart, which is one more reason a single "dose" number for TB-500 is misleading without its model and route attached.
Material handling rounds out the practical picture. TB-500 is supplied as a lyophilized powder for research use and reconstituted in bacteriostatic or sterile water, kept refrigerated [5]. As a short acetylated peptide it is more chemically robust than the full-length protein, but it remains subject to proteolysis and freeze-thaw degradation, and the identity and purity of research-grade material — including whether a vial actually contains the fragment rather than mislabeled full-length Tβ4 — is a recurring concern in unregulated supply [5]. That quality variability is itself a reason anecdotal dose-response reports are hard to interpret.
TB-500 half-life
TB-500 half-life, for the heptapeptide specifically, is not a validated number. No validated human pharmacokinetic half-life exists for the Ac-LKKTETQ fragment [5]. What can be cited is the parent protein: in the IV full-length Tβ4 Phase 1 study, half-life increased with dose, consistent with dose-proportional pharmacokinetics [6]. Anti-doping LC-MS work has characterized TB-500 and its metabolites in equine plasma and urine, but that work exists to support detection, not to establish human PK [5].
As a short, N-acetylated peptide, the fragment is more chemically robust than the full-length protein, but it is still subject to proteolysis and freeze-thaw degradation; it is supplied lyophilized and reconstituted in bacteriostatic or sterile water for research use [5]. Any half-life figure attached to the fragment in human use is an estimate, not a measured value.
TB-500 half-life
No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide [5]. In the IV full-length thymosin beta-4 Phase 1 study, half-life increased with dose (dose-proportional PK) [6] — but that is the parent protein, not the 7-mer. Equine anti-doping LC-MS work characterizes the fragment for detection, not for human pharmacokinetics.